期刊
DIABETIC MEDICINE
卷 25, 期 10, 页码 1151-1156出版社
WILEY
DOI: 10.1111/j.1464-5491.2008.02565.x
关键词
diabetes; guideline; macrovascular; postmeal glucose; self-monitoring of blood glucose
资金
- Amylin Pharmaceuticals
- Eli Lilly and Company
- LifeScan Inc
- Merck Co. Inc
- Novo Nordisk A/S
- Roche Diagnostics GmbH
- Roche Pharmaceuticals
Diabetes is a significant and growing concern, with over 246 million people around the world living with the disease and another 308 million with impaired glucose tolerance. Depending on the resources of different nations, intervention has generally focused on optimizing overall glycaemic control as assessed by glycated haemoglobin (HbA(1c)) and fasting plasma glucose (FPG) values. Nevertheless, increasing evidence supports the importance of controlling all three members of the glucose triad, namely HbA(1c), FPG and postmeal glucose (PMG) in order to improve outcome in diabetes. As part of its global mission to promote diabetes care and prevention and to find a cure, the International Diabetes Federation (IDF) recently developed a guideline that reviews evidence to date on PMG and the development of diabetic complications. Based on an extensive database search of the literature, and guided by a Steering and Development Committee including experts from around the world, the IDF Guideline for Management of Postmeal Glucose offers recommendations for appropriate clinical management of PMG. These recommendations are intended to help clinicians and organizations in developing strategies for effective management of PMG in individuals with Type 1 and Type 2 diabetes. The following review highlights the recommendations of the guideline, the supporting evidence provided and the major conclusions drawn. The full guideline is available for download at www.idf.org.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据